AU2017272862A1 - Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein - Google Patents

Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein Download PDF

Info

Publication number
AU2017272862A1
AU2017272862A1 AU2017272862A AU2017272862A AU2017272862A1 AU 2017272862 A1 AU2017272862 A1 AU 2017272862A1 AU 2017272862 A AU2017272862 A AU 2017272862A AU 2017272862 A AU2017272862 A AU 2017272862A AU 2017272862 A1 AU2017272862 A1 AU 2017272862A1
Authority
AU
Australia
Prior art keywords
formula
conjugate
pct
ring
pmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017272862A
Other languages
English (en)
Inventor
Stefan Petry
Oliver Plettenburg
Norbert Tennagels
Ulrich Werner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2017272862A1 publication Critical patent/AU2017272862A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/12Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AU2017272862A 2016-06-02 2017-06-02 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein Abandoned AU2017272862A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305640 2016-06-02
EP16305640.1 2016-06-02
PCT/EP2017/063447 WO2017207754A1 (en) 2016-06-02 2017-06-02 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein

Publications (1)

Publication Number Publication Date
AU2017272862A1 true AU2017272862A1 (en) 2019-01-17

Family

ID=56121007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017272862A Abandoned AU2017272862A1 (en) 2016-06-02 2017-06-02 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein

Country Status (13)

Country Link
US (3) US11090364B2 (enExample)
EP (1) EP3463480A1 (enExample)
JP (1) JP2019520342A (enExample)
KR (1) KR20190015413A (enExample)
CN (1) CN109562185A (enExample)
AU (1) AU2017272862A1 (enExample)
BR (1) BR112018074716A2 (enExample)
CA (1) CA3025988A1 (enExample)
IL (1) IL263390A (enExample)
MX (1) MX2018014929A (enExample)
RU (1) RU2018147235A (enExample)
SG (1) SG11201810701XA (enExample)
WO (1) WO2017207754A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025988A1 (en) * 2016-06-02 2017-12-07 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
CN111433193A (zh) 2017-12-01 2020-07-17 赛诺菲 药剂和能够结合至葡萄糖传感蛋白的部分的新型缀合物
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
CN115920081B (zh) * 2022-11-02 2024-07-19 重庆大学 红细胞膜自发定向包被ros响应的纳米前药及其应用
WO2025199666A1 (en) * 2024-03-25 2025-10-02 Canwell Biotech Limited Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
JP2003535106A (ja) 2000-06-02 2003-11-25 ノボ ノルディスク アクティーゼルスカブ グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
CN101638423B (zh) 2008-07-29 2012-09-05 常州高新技术产业开发区三维工业技术研究所有限公司 根皮苷衍生物及其制备方法和用途
US20110230403A1 (en) 2008-09-19 2011-09-22 Novartis Ag Glycoside derivatives and uses thereof
WO2010088300A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
BRPI1007457A2 (pt) * 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
CA2794266C (en) * 2010-03-24 2020-09-08 Ohio University Compositions and methods for glucose transport inhibition
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
WO2013121296A1 (en) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
JP2014510782A (ja) 2011-04-14 2014-05-01 ノバルティス アーゲー グリコシド誘導体およびその使用
PL2721045T3 (pl) 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
KR20140145148A (ko) 2012-03-21 2014-12-22 에리테끄 파르마 급성 골수성 백혈병 치료를 위한 약제
WO2013182612A1 (en) * 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
KR20160065930A (ko) 2013-10-04 2016-06-09 머크 샤프 앤드 돔 코포레이션 글루코스-반응성 인슐린 접합체
ES2742102T3 (es) 2014-01-15 2020-02-13 Baseclick Gmbh Moléculas de ácido nucleico modificadas con sacárido
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
WO2017124102A1 (en) * 2016-01-14 2017-07-20 North Carolina State University Glucose responsive insulin delivery compositions and methods
CA3025988A1 (en) 2016-06-02 2017-12-07 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein

Also Published As

Publication number Publication date
WO2017207754A1 (en) 2017-12-07
CA3025988A1 (en) 2017-12-07
SG11201810701XA (en) 2018-12-28
BR112018074716A2 (pt) 2019-03-12
RU2018147235A (ru) 2020-07-10
US20210401947A1 (en) 2021-12-30
KR20190015413A (ko) 2019-02-13
IL263390A (en) 2018-12-31
US11090364B2 (en) 2021-08-17
JP2019520342A (ja) 2019-07-18
US20190209656A1 (en) 2019-07-11
MX2018014929A (es) 2019-08-26
US20210401946A1 (en) 2021-12-30
CN109562185A (zh) 2019-04-02
EP3463480A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
US20210401947A1 (en) Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
US11981666B2 (en) GLP-1 receptor agonist and composition and use thereof
KR20240036506A (ko) 엑사테칸 유도체 및 그의 항체-약물 접합체
BR112019021810A2 (pt) Sistemas de liberação prolongada que compreendem ligantes não vestigiais
BRPI0607248A2 (pt) conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado
KR20240036604A (ko) Asgpr 세포 표면 수용체 결합 화합물 및 접합체
JP2022524678A (ja) ガレクチンのα-D-ガラクトシド阻害剤
JP2022538312A (ja) ガレクチンの新規なガラクトシド阻害剤
WO2011024001A1 (en) Np-1 antagonists and their therapeutic use
KR20120046162A (ko) 2,3-디히드로-1h-인덴 화합물 및 이의 암치료 용도
CN106661002A (zh) 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的任选稠合的、经杂环基取代的嘧啶衍生物
CN114349738A (zh) 一类靶向降解cdk2的小分子缀合物及其应用
EP2998294A1 (en) Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
CN118894846A (zh) 一种含硒元素类化合物及其用途
KR20200116137A (ko) 백혈병, 림프종 및 고형 종양의 치료에 사용하기 위한 4-(1H-이미다졸-5-일)-1H-피롤로[2,3-b]피리딘
PT2370442E (pt) 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina
TW202100514A (zh) 芳香族衍生物其製備方法和醫學用途
WO2019106122A1 (en) Novel conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
US20250066359A1 (en) Somatostatin receptor subtype 5 antagonists, and pharmaceutical composition and use thereof
US20240150351A1 (en) Bicyclic compounds
JP2025530891A (ja) リソソーム内の細胞外標的の分解を選択的に誘導する二機能性分子
RS67310B1 (sr) Derivat aril glukozida i njegova upotreba u leku
AU2012245702A1 (en) Diazonamide analogs
WO2025207934A1 (en) Lysosomal targeting bifunctional molecules for degradation of thyroid stimulating hormone receptor autoantibodies
WO2025035040A1 (en) Lysosomal targeting bifunctional molecules for degradation of muscle-specific kinase autoantibodies

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period